Lineage Cell Therapeutics Statistics
NYSE: LCTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
0.9476+0.0097 (+1.03%)
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Lineage Cell Therapeutics by the numbers
Lineage Cell Therapeutics has a market capitalization of $239.7 million based on 252.91M shares outstanding. With trailing EPS of $-0.19, Lineage Cell Therapeutics is unprofitable on a 12-month basis, so earnings-based valuation ratios do not apply. The stock trades 10.3% below its 50-day average and 31.9% below its 200-day average.
Average daily trading volume is 1.15M shares, or about $1.1 million in dollar volume.
Summary generated from market data by MetaCap's automated system. Methodology
LCTX valuation vs. peer median
| Metric | LCTX | Peer median | Difference |
|---|---|---|---|
| Market cap | $239.66M | $237.43M | +1% |
| Avg. volume | 1.15M | 1.32M | -13% |
Peer median across 8 companies: IPSC, STRO, PLX, FATE, PALI, IVVD, ALEC, SABS.
Valuation
- Market cap
- $239.66M
- EPS (TTM)
- $-0.19
- Shares outstanding
- 252.91M
Price and trading
- Previous close
- 0.9379
- Open
- 0.9424
- Day range
- 0.9212 – 0.965
- 52-week range
- 0.88 – 2.09
- 52-week change
- -45.23%
- Beta
- —
- Volume
- 1.48M
- Average volume
- 1.15M
Dividends and events
- Annual dividend
- None
- Next earnings date
- Nov 5, 2026
Additional statistics
- Market Cap
- 239.66M
- Forward Pe
- -6.89
- Eps
- -0.19
- Dividend Yield
- 0.00%
- Dividend Rate
- 0.00
- Week52 High
- 2.09
- Week52 Low
- 0.88
- Avg Volume
- 1.15M
- Shares Outstanding
- 252.91M
- Ma50
- 1.06
- Ma200
- 1.39
- Earnings Date
- Nov 5, 2026
- Pct From52w High
- -54.66%
- Pct From52w Low
- 7.68%